alexa Development And Preclinical Evaluation Of 15 Pneumococcal Polysaccharide CRM197 Conjugate Candidate Vaccines In Mouse Model
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Huyen T Pham, Chanwoo Park, Kim Doh Hoon, Ju-Hwan Kim, Hyo-Jin Kang, Do-Young Yoon, Rock-Ki Kim, Sung-Kyun Lee, Yoon-Hee Whang, Chan-Kyu Lee and Suenie Park
Konkuk University, South Korea
Dongguk University, South Korea
EuBiologics Co. Ltd, South Korea
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
Statement of the Problem: Pneumococcal capsular polysaccharides (PnPS) are the most important virulence factor of the human pathogen Streptococcus pneumoniae, which shield pneumococci from host phagocytes. Conjugation of the PnPS to a protein carrier enhances immunologic responses to the vaccine, leading to protection against infection. Current vaccines based on the use of a limited number of PnPS and conjugated PnPS have been licensed including PPSV23 (Pneumovax) and PCV13 (Prevnar13). To compensate the defect, new vaccines against more serotypes are being developed. Methodology & Theoretical Orientation: In our study, we engineered antigens from polysaccharides or CRM197-conjugated polysaccharides which are potential to become vaccines. The treatment groups (6-week-old BALB/c mice) were vaccinated intraperitoneally (IP) with 1 dose (100 μg of polysaccharide antigen/mouse), or (2.5 μg of CRM197-conjugated polysaccharide antigen/mouse) three times at 4-week intervals. After vaccination, specific antibodies against PnPS of each serotype (1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F and 23F) were measured by enzyme-linked immunosorbent assay (ELISA) and functional IgG was detected by opsonophagocytic killing assay (OPA). Findings: There were good antibody responses of mice to both antigens, as compared to the baseline. In ELISA, most of the end-point titers from conjugated antigens were higher than unconjugated ones. Besides, the antisera from vaccinated mice contained functional opsonic antibodies demonstrated by OPA. Conclusion & Significance: The 15 developed-pneumococcal-conjugate vaccines manufactured by a Korean company have the effectiveness of serological immunogenicity in mouse model. These results implicate to develop a newly 15-valent pneumococcal conjugate vaccine (PCV15) and would provide the further possibility of the clinical application.

Huyen T Pham is a PhD candidate in Immunology Research in the Department of Bioscience and Biotechnology, Konkuk University, Seoul, South Korea. She is currently working for Professor Do-Young Yoon at Konkuk University, where she manages projects focused on inflammation, interleukin 32 and pneumoniae vaccine research. She obtained her Master’s degree in Proteomics in the Department of Molecular Biotechnology, Konkuk University, South Korea

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version